OSE Immunotherapeutics SA s is a biotechnology company, which engages in the research and development of pharmaceutical products. The company is headquartered in Nantes, Pays De La Loire and currently employs 64 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
Follow-Up Questions
Quelle est la performance du prix de l'action ORPOF ?
Le prix actuel de ORPOF est de $0, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de OSE Immunotherapeutics SA ?
OSE Immunotherapeutics SA appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de OSE Immunotherapeutics SA ?
La capitalisation boursière actuelle de OSE Immunotherapeutics SA est de $NaN
Est-ce que OSE Immunotherapeutics SA est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 6 analystes ont établi des notations d'analystes pour OSE Immunotherapeutics SA, y compris 1 achat fort, 6 achat, 1 maintien, 0 vente et 1 vente forte
